

# Wake Forest University School of Medicine

## Curriculum Vitae

**NAME:** Marina Núñez, MD, PhD

**CURRENT ACADEMIC TITLE:** Instructor

**ADDRESS:**

**BUSINESS:** Section on Infectious Diseases  
Wake Forest University Health Sciences  
Medical Center Boulevard  
Winston-Salem, NC 27157-1042  
Telephone: (336) 716-4262  
Fax: (336) 716-3825

**EDUCATION:**

1982-1988 Medical School of Navarra University  
Pamplona (Navarra), Spain  
M. D.

1995-96 Medical School of Navarra University  
Pamplona (Navarra), Spain  
Ph.D. (*Cum Laude*)

**POSTDOCTORAL TRAINING:**

1990-94 Residency – Internal Medicine  
Navarra University Clinic  
Pamplona (Navarra), Spain.

1996-1998 Fellowship - Infectious Diseases.  
Wake Forest University Baptist Medical Center,  
Winston-Salem, NC, US

1999-2000 Master on "Design and Statistics in Health Science".  
July 2000, Universidad Autónoma de Barcelona,  
Spain.

**PROFESSIONAL LICENSURE:**

May 2006 North Carolina #00499

**EMPLOYMENT:**

1998-2006 Infectious Diseases Specialist  
Hospital Carlos III, Madrid (Spain)

**OTHER PROFESSIONAL APPOINTMENTS AND INSTITUTIONAL SERVICE:**

2004-Present Contributor for the web-based medical site  
[www.HIVandhepatitis.com](http://www.HIVandhepatitis.com)

2005 Reviewer of grant application for the National  
Institute of Health. Washington DC.

200-2005 Reviewer for peer-reviewed journals:  
Journal of Infectious Diseases  
HIV Clinical Trials  
Enfermedades Infecciosas y Microbiología Clínica  
Journal of Infection  
Expert Opinion on Pharmacotherapy (EOP)

1999-2005 Assistant teacher in the Master Program on AIDS.  
Hospital Carlos III & School of Medicine of the  
Universidad Complutense de Madrid

1994-1996 Assistant teacher of Human Physiology, Medical  
School of the University of Navarra

**PROFESSIONAL MEMBERSHIPS:**

None currently.

**COMMITTEES:**

None currently

**PROFESSIONAL INTERESTS:**

Clinical research on Hepatitis C and B infections in the HIV setting.

**GRANTS:**

-Fondo de Investigaciones Sanitarias (#02/3040), 2003-2006. Project: Chronic hepatitis C in HIV infection: virological and pharmacological interactions.

- CAM (Comunidad Autónoma de Madrid) (2003-2004). Project: Modulation of the apoptosis as a new therapeutical target in the antibacterial defense (# 08,2,0010,1)
- CAM (Comunidad Autónoma de Madrid), 1999. Project: Optimal use of the protease inhibitors in HIV positive patients based on genotypic resistance patterns.
- Danone Institute, 1995. Project: Effect of low doses of recombinant human insulin-like growth factor I (rhIGF-I) on nutritional status and sugar absorption in CCl<sub>4</sub>-induced cirrhotic rats. (Results presented for Master Degree).

#### HONORS AND AWARDS

1995

Best poster presented at the XXII Congreso Nacional de la Sociedad Española de Patología Digestiva. Madrid, Spain

#### BIBLIOGRAPHY:

1. **M Núñez**, B Diaz-Pollan, N Camino, et al. Virological Outcome of Chronic Hepatitis B Virus Infection in HIV-Coinfected Patients Receiving anti-HBV Active Antiretroviral Therapy. *AIDS Res Hum Retroviruses* 2006; 22 (in press).
2. **M Núñez**, V Soriano, M López, et al. Co-infection with hepatitis C virus increases lymphocyte Apoptosis in HIV-Infected Patients. *Clin Infect Dis* 2006 (in press).
3. B Ramos, **M Núñez**, C Toro. Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: Implications for HCV therapy in HCV/HIV-coinfected patients. *J Infect* 2006 (in press).
4. V Soriano, **M Núñez**, J Garcia-Samaniego, et al. Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less. *Infect Disord Drug Targets* 2006; 6:57-88.
5. I Maida, **M Núñez**, B Ramos, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. *J Acquir Immune Defic Syndr* 2006;42:177-82.
6. **M Núñez**. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. *J Hepatology* 2006; 44 (Suppl 1): S132-S139
7. I Maida, S Babudieri, C Selva, G D'Offizi, L Fenu, G Solinas, P Narciso, M Mura, **M Núñez**. Liver enzyme elevations in hepatitis C virus (HCV)-HIV-coinfected patients prior and after initiating HAART: role of HCV genotypes. *AIDS Res and Hum Retr* 2006; 22:139-43.
8. V Soriano, P Barreiro, **M Núñez**. Management of chronic hepatitis B and C in HIV-coinfected patients. *J Antimicrob Chemother* 2006; 57:815-8.

9. V Soriano, J Sheldon, B Ramos, **M Núñez**. Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons. *AIDS* 2006; 20:451-3.
10. **M Núñez**. Highlights from the 1st Internacional Workshop on HIV and Hepatitis Co-infection. *HIV Clin Trials* 2005; 6:118-25.
11. V Soriano, B Ramos, **M Núñez**, et al. Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C genotype. *J Infect Dis* 2005; 192:1245-48.
12. V Soriano, **M Núñez**, J Sheldon, et al. Complications in treating chronic hepatitis B in patients with HIV. *Expert Opin Pharmacother* 2005; 6:2831-42.
13. **M Núñez**, N Camino, B Ramos, M Berdún, et al. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. *Antivir Ther* 2005; 10:657-62.
14. A Rendón, **M Núñez**, I Jiménez-Nácher, D González de Requena, J González-Lahoz, V Soriano. Clinical Benefit of interventions driven by therapeutic drug monitoring. *HIV Med* 2005; 6:360-65.
15. **M Núñez**, V Soriano. Current concepts in the management and treatment of hepatitis C in HIV-infected patients. *Ann Hepatol* 2005; 4:151-60.
16. V Soriano, L Martín-Carbonero, I Maida, J García-Samaniego, **M Núñez**. New paradigms in the management of HIV and hepatitis C virus coinfection. *Curr Opin Infect Dis* 2005; 18:550-60.
17. **M Núñez**, V Soriano. Management of patients co-infected with hepatitis B virus and HIV. *Lancet Infect Dis*. 2005; 5:374-82.
18. **M Núñez**, I Maida, S Babudieri, et al. Hepatitis C viremia in HIV/HCV-coinfected patients: lower levels in presence of chronic hepatitis C. *HIV Clin Trials* 2005; 6:103-106.
19. A Rendón A, **M Núñez**, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virological response in HIV/hepatitis C virus-coinfected patients. *J Acquir Immune Defic Syndr* 2005; 39:401-405.
20. **M Núñez**, V Soriano. Risks and benefits of antiretroviral therapy in HIV-HCV co-infected patients. *J Hepatol* 2005; 42:290-2.
21. V Soriano, **M Núñez**, M Sánchez-Conde, et al. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4. *Antivir Ther* 2005;10:167-70.
22. **M Núñez** and V Soriano. Hepatitis C Virus (HCV) Genotypes and Disease Progression in HIV/HCV-Coinfected Patients. *Journal of Infectious Diseases* 2005; 191:1-3.

23. **M Núñez** and V Soriano. Hepatotoxicity of antiretrovirals. Incidence, mechanisms, and management. *Drug Safety* 2005; 28:53-66.
24. I Maida, **M Núñez**, J Gonzalez-Lahoz, V Soriano. Liver transplantation in HIV-HCV coinfecting candidates. What is the most appropriate time for evaluation? *AIDS Res Hum Retroviruses* 2005;21:599-601.
25. **M Núñez**, V Soriano . How effective is HAART in HCV and HIV coinfection? *AIDS* 2004; 18:2081-2084.
26. **M Núñez** and V Soriano. New hopes for HIV and HCV coinfection in 2004. *HIV Clinical Trials* 2004; 5:232-251.
27. **M Núñez**, García-Samaniego J, Soriano V. Advances in the diagnosis and treatment of the infection by the hepatitis B virus. *Enferm Infecc Microbiol Clin* 2004; 29:539-550.
28. V Soriano, I Maida, **M Núñez**, et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. *Antivir Ther* 2004; 9:987-92.
29. D González-Requena D, **M Núñez**, J González-Lahoz, Soriano V. Liver toxicity of lopinavir-containing regimens in HIV-infected patients with and without hepatitis C coinfection. *AIDS Res Hum Retroviruses* 2004; 20:698-700.
30. Barreiro P, Corbatón A, **Núñez M**, González-Lahoz J, Soriano V. Tolerance of didanosine as enteric-coated capsules versus buffered tablets. *AIDS Patient Care STDS* 2004; 18:329-331.
31. Maida I, **Núñez M**, Soriano V. Triple-nucleoside regimens versus efavirenz. *N Engl J Med* 2004; 351:717-9.
32. Soriano V, **Núñez M**, Camino N, et al. Hepatitis C virus-RNA clearance in HIV-coinfecting patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. *Antivir Ther* 2004; 9:505-509.
33. **Núñez M**, Puoti M, Camino N, Soriano V. Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. *Clin Infect Dis.* 2003; 37 :1678-85.
34. Rendón AL, **Núñez M**, González-Requena D, Jiménez-Nácher I, González-Lahoz J, Soriano V. Diarrhea related to lopinavir is most often mild and not related to plasma drug levels. *J Acquir Immune Defic Syndr.* 2003 Oct 1;34(2):247.
35. Pérez-Olmeda M, **Núñez M**, García-Samaniego J, Ríos P, Gonzalez-Lahoz J, Soriano V. Distribution of hepatitis B virus genotypes in HIV-infected patients with chronic hepatitis B: therapeutic implications. *AIDS Res Hum Retroviruses.* 2003 Aug;19(8):657-9.

36. **Núñez M**, Martín-Carbonero L, Soriano V. Impact of hepatitis C virus (HCV) on morbidity and mortality rates among HIV-infected patients. *Clin Infect Dis*. 2003 Aug 1;37(3):460-1.
37. Pérez-Olmeda M, **Núñez M**, Romero M, González J, Castro A, Arribas JR, Pedreira J, Barreiro P, García-Samaniego J, Martín-Carbonero L, Jiménez-Nácher I, Soriano V. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. *AIDS*. 2003 May 2;17(7):1023-8.
38. Martín-Carbonero L, **Núñez M**, González-Lahoz J, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. *HIV Clin Trials* 2003; 4:115-20.
39. Soriano V, Pérez-Olmeda M, Ríos P, **Núñez M**, García-samaniego J, González-Lahoz J. Is treatment failure for hepatitis C virus infection in HIV-positive drug users associated with a shift in HCV genotypes?. *J Acquir Immune Defic Syndr* 2003; 32:465-66.
40. **Núñez M**, Pérez-Olmeda M, González-Lahoz J, Soriano V. Hepatitis B virus infection despite receiving lamivudine in one HIV-infected person. *HIV Clin Trials*. 2003 Jan-Feb;4(1):77-8.
41. **Núñez M**, Pérez-Olmeda M, González-Lahoz J, Soriano V. Reactivation of hepatitis B virus after lamivudine withdrawal in HIV-infected patients. *HIV Clinical Trials* 2003.
42. **Núñez M**, Asenci R, Valencia E, Leal M, González-Lahoz J, Soriano V. Rate, causes and clinical implications of presenting with low CD4 counts in the HAART era. *AIDS Research and Human Retroviruses* 2003; 19:363-68.
43. **Núñez M**, Soriano V, González-Requena D, González-Lahoz J. Interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity. *AIDS Research and Human Retroviruses* 2003; 19:187-88.
44. Camino N, **Núñez M**, Blanco F, González-Requena D, González-lahoz J, Soriano V. Case report: Indinavir-induced thrombocytopenia. *AIDS Patient Care* 2003; 17:99-100.
45. González-Requena D, **Núñez M**, Soriano V. Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations. *AIDS* 2003; 17:442-44.
46. **Núñez M**, Pérez-Olmeda M, Díaz B, Ríos P, González-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. *AIDS* 2002; 16:2352-2354.
47. González-Requena D, **Núñez M**, Gallego O, Jiménez-Nácher I, González-Lahoz J, Soriano V. Does an increase in nevirapine plasma levels cause complete virologic

- suppression in patients experiencing early virologic failure? HIV Clin trials 2002; 3:463-67.
48. **Núñez M**, De Mendoza C, Valer L, Casas E, López-Calvo S, Castro A, Rosón B, Podzamczar D, Rubio A, Berenguer J, Soriano V. Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations. Med Sci Monit 2002; 8(9):CR620-623.
  49. **Núñez M**, Ríos P, Pérez-Olmeda M, Soriano V. Lack of "occult" hepatitis B virus infection in HIV-infected patients. AIDS 2002; 16:2099-2101.
  50. **Núñez M**, Soriano V, Martín-Carbonero L, Barrios A, Barreiro P, Blanco F, García-Benayas T, González-Lahoz J. SENC (Spanish Efavirenz vs. Nevirapine Comparison) trial: a randomized, open-label study in HIV-infected naïve individuals. HIV Clinical Trials 2002; 3:186-194.
  51. **Núñez M**, Ríos P, Martín-Carbonero L, Pérez-Olmeda M, González-Lahoz J, Soriano V. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Def Syndr 2002; 30:65-8.
  52. Martín-Carbonero L, **Núñez M**, Ríos P, Pérez-Olmeda M, González-Lahoz J, Soriano V. Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. AIDS 2002; 16:1423-1425.
  53. González de Requena D, **Núñez M**, Jiménez-Nácher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002; 16:290-1.
  54. Pérez-Olmeda M, Ríos P, **Núñez M**, García-Samaniego J, Romero M, Soriano V. Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment. AIDS 2002; 16:493-5.
  55. **Núñez M**, Soriano V, González-Lahoz J. Clinical manifestations of HIV infection in the HAART era. AIDS Rev 2001; 3:3-10.
  56. **Núñez M**, Lana R, Mendoza J, Martín-Carbonero L and Soriano V. Risk Factors for Severe Hepatic Injury Following the Introduction of Highly Active Antiretroviral Therapy. J AIDS 2001; 27:426-431.
  57. **Núñez M, Saballs P, Valencia ME, Santos J, Ferrer E, Santos I, Berrocal A, Galindo MJ, Podzamczar D, Gonzalez-Lahoz J, and the Caelyx/KS Spanish Study Group. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy. HIV Clinical Trials 2001; 2:429-437.**

58. **Núñez M**, González de Requena D, Gallego L, Jiménez-Nácher I, Soriano V a González-Lahoz J. Higher Efavirenz Plasma Levels Correlate with the Development of Insomnia. *J AIDS* 2001; 28:399-404.
59. Lana R, **Núñez M**, Mendoza JL, and Soriano V. Incidencia y factores predictivos de hepatotoxicidad en pacientes que reciben terapia antirretroviral de gran actividad. *Med Clin (Barcelona)* 2001;117:607-10.
60. **Núñez M**, Rodriguez-Rosado R, and Soriano V. Intensification of antiretroviral therapy. *AIDS Research and Human Retroviruses* 2001;17:499-506.
61. Díaz B, **Núñez M**, Soriano V. Hepatitis B aguda en un paciente con infección por el virus de la inmunodeficiencia humana previamente vacunado. *Med Clin (Barcelona)* 2001; 117:50-51.
62. **Núñez M**, and Soriano V. Salvage therapy for HIV infection: when and how. *AIDS Patient Care and STDs* 2000;14:465-476.
63. **Núñez M**, Peacock J, and Chin R. Pulmonary cryptococcosis in the immunocompetent host. Therapy with oral fluconazole: a report of four cases and a review of the literature. *Chest* 2000;118:527-534.
64. **Núñez M**, Machuca A, Soriano V, Podzamczar D, González-Lahoz J, and the Caelyx/KS Spanish Study Group. Clearance of HHV-8 viraemia in HIV-1 positive patients with Kaposi's Sarcoma treated with liposomal doxorubicin. *AIDS* 2000; 14:913-919.
65. **Núñez M**, Barreiro P, and Soriano V. Simplifying antiretroviral therapy. *AIDS Reviews* 2000; 2:93-98.
66. **Núñez M** and Soriano V. Cancer y virus de la inmunodeficiencia humana en la era de la terapia combinada. *Medicina Clínica* 2000;115:93-94.
67. **Núñez M**, Machuca A, and Soriano V. HHV-8: an always intriguing, sometimes relevant herpesvirus. *AIDS Reviews* 2000;1:23-30.
68. **Núñez M**, González-Lahoz J. Síndrome de Lipodistrofia: Nuevo Desafío en el Tratamiento de la Infección por VIH. *Información Terapeutica* 2000;24:69-72.
69. **Núñez M**, Peacock J. Mycetoma of the calf due to *Nocardia brasiliensis*. *Infectious Diseases in Clinical Practice* 1999; 8(2):107-108.
70. **Núñez M**, Radford J, Cruz J, Perry J, Hurd D and High K. Tuberculosis after bone marrow transplantation. *Infectious Diseases in Clinical Practice* 1999; 8(3): 172-176.
71. Quiroga J, Sangro B, **Núñez M**, et al. Transjugular intrahepatic portosystemic shunt in the treatment of refractory ascites. Effect on clinical, renal, humoral and hemodynamic parameters. *Hepatology* 1995;21:986-993.

72. **Núñez M**, Beloqui O, Herrero I, Prieto J. Mastitis de repetición y Síndrome de Hiperinmunoglobulinemia E. Revista Clínica Española 1992;191:503.

**Chapters and monographies:**

1. **Núñez M**, Soriano V. Hepatotoxicidad del tratamiento antirretroviral. In: Soriano V y González-Lahoz J (Eds) Coinfección por VIH y virus de la hepatitis C, 2003. Permanyer, Barcelona.
2. **Núñez M**, Soriano V. Manifestaciones clínicas de la infección por VIH en la era HAART. In: Soriano V y González-Lahoz J (eds.). Manual del SIDA, 4ª ed. Ediciones Permanyer. Barcelona.
3. **Núñez M**, Soriano V. Conceptos básicos de la terapia antirretroviral de rescate. In: Soriano V (ed.). Biblioteca del SIDA. Terapia antirretroviral de rescate 2001. Ediciones Permanyer. Barcelona.
4. **Núñez M** y González-Lahoz J. Complicaciones metabólicas de la terapia antiretroviral. Síndrome de lipodistrofia. In: Usieto R (ed.). Adherencia terapéutica y calidad de vida en la infección por VIH/SIDA 2000. Ediciones CESA. Madrid.
5. **Núñez M** y González-Lahoz J. Virus Herpes Humano tipo 8 (HHV-8). In: Gonzalez-Lahoz J, y Soriano V (eds.). Enfermedades víricas en la infección por VIH 2000. Ediciones IM&C. Madrid
6. **Núñez M**, Blanco F, y González-Lahoz J. Efectos secundarios de los fármacos antirretrovirales: toxicidad a largo plazo. In: Soriano V (ed.). Biblioteca del SIDA. Toxicidad e interacciones de los fármacos antirretrovirales 2000. Ediciones Permanyer. Barcelona.

**Oral Presentations at Conferences:**

- |      |   |
|------|---|
| 2005 | “Interferon-alfa exposure for the treatment of hepatitis C could impair immune recovery in HIV-infected patients under antiretroviral therapy”. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. December 2005. Washington DC, US |
| 2005 | “Virological outcome of chronic hepatitis B virus (HBV) infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy”. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. December 2005. Washington DC, US |

- 2004 "Efficacy and safety of peginterferon- $\alpha$ -2a (40KD) plus ribavirin (peg-IFN+RBV) for the treatment of hepatitis C in HIV co-infected patients: interim results of the PRESCO trial". 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. October-November 2004. Washington DC, US
- 2003 "Hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients". 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. September 2003. Chicago, US
- 2002 "Lack of "occult" hepatitis B virus infection in HIV-infected patients" 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. September 2002. San Diego, US
- 2000 The SENC trial: Spanish Efavirenz versus Nevirapine Comparison Trial. Preliminary results of a prospective, randomized, controlled, open-label study in HIV+ naïve individuals." 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 2000. Toronto, Canada.

#### **COMMUNITY SERVICE**

None currently

#### **PERSONAL INTERESTS**

Art and literature

Updated August 1<sup>st</sup>, 2006